16 YEARS OF INTERNATIONAL CLINICAL EXPERIENCE IN TRANSPLANTATION OF HUMAN EMBRYONIC/FETAL STEM CELLS
Welcome to Cell Therapy Clinic EmCell
Our clinic offers embryonic stem cell treatment to help people improve their health. In 16 years, we treated thousands of patients with various diseases and conditions such as:
- Diabetes Mellitus (types 1 and 2)
- Multiple Sclerosis
- Parkinson's Disease
- Duchenne's and Other types of muscular dystrophy
- Cancer
- Blood Diseases
- Rare Genetic and Hereditary Diseases
- Aging
- and many other diseases and conditions
We have performed more than 5,000 transplantations of embryonic stem cells of people from different countries of the world. Our treatment helped to save and prolong life as well as improve quality of life of thousands of patients; it is effective for restoration of different organs and tissues, and we were able to prove that embryonic stem cells can ignite hope in many people with incurable diseases.
EmCell is a private clinic founded in 1994. Many years of intensive work won EmCell team international recognition in the field of research and clinical application of embryonic stem cells.
At present, this highly efficient and creative team is made of like-minded professionals guided by Prof. Alexander Ivanovich Smikodub who use embryonic stem cells in vivo, work out indications and contraindications for the treatment of severe acquired and genetic diseases caused by or resulting in cell count reduction.
In its program aired on November 17, 2005, BBC called our facility the Last Hope Clinic because for 16 years we treated and followed-up the most complex clinical cases. Apart from this, clinic offers effective prevention and anti-aging programs.
Please Click Here to request more information from EmCell Clinic.
Treatments & Prices
Major indication for transplantation of embryonic stem cells is reduction of the number of cell due to disease or other factors (radiation, stress, aging etc.), which means that our method of treatment is effective in a wide range of diseases and conditions including but not limited to those listed below:
- diseases of nervous system (neurodystrophy, Alzheimer's disease, Parkinson's disease, Pick's disease, multiple sclerosis, amyotrophic lateral sclerosis, condition after meningoencephalitis, traumatic brain injury, spinal cord injury, condition after neurosurgery, Duchenne's and other muscular dystrophies etc.)
- hematological diseases (different types of anemia (primary and secondary), sickle cell disease, leucopenia, agranulocytosis, thrombocytopenia, acute and chronic leucosis, lymphoma, lymphosarcoma etc.)
- malignancy and cancer (effective treatment allowing for radical treatment in cases of complications, better endurance of aggressive chemo- and radiotherapy and anti-tumor immunity formation, life expectancy prolongation, higher survival rate)
- diabetes mellitus (both types 1 and 2)
- intestinal diseases (ulcerative colitis, Crohn's disease, colitis of other etiology)
- autoimmune diseases (systemic lupus erythematosa, rheumatoid arthritis, collagenosis etc.)
- liver diseases (chronic hepatitis, liver cirrhosis)
- diseases of joints (deforming arthrosis, oligo-, mono- and polyarthritis)
- vascular diseases
- genetic diseases
- immune system diseases (AIDS/HIV, immune deficiency of different etiology)
- ophthalmological diseases (retinitis pigmentosa, macular dystrophy, retinopathy, both primary and secondary etc.)
- chronic infections, sepsis
- sexual diseases
- sexual dysfunction (impotence, fading potency, male and female sterility, pyospermia, acute and chronic infections)
- aging and age-related problems (deterioration of internal organs, general health, fatigue, premature aging, skin problems etc.)
- climax (female and male)
- stress-related problems (chronic fatigue syndrome, anxiety etc.)
Major Curative Effects of Embryonic Stem Cell Transplantation
There are 5 main curative effects of embryonic stem cell transplantation:
- Rapid and substantial improvement of volitional, mental and physical activities of patients, stabilization and improvement of mood, positive psychophysiological changes, particularly in such areas as attention, memory, and mental performance;
- Restoration of suppressed hematopoiesis (normalization of erythrocyte, leukocyte, lymphocyte, and thrombocyte counts);
- Stimulation, correction, or suppression of immune system (depending on what is beneficial for the patient in his/her current condition, or stage of the disease);
- Stimulation of trophic functions in tissues and organs, marked improvement in cases of deteriorated tissues, impaired functions, processes of aging, and a very vivid effect of functional "rejuvenation");
- Normalization of homeostasis (glycemia, lipidemia, creatinemia, mineral and water metabolism, blood pressure, improvement of blood circulation, etc.).
Each type of stem cells produce specialized curative effects that should not be attributed to some universal stem cells. The best results are achieved by combination of different kinds of stem cells depending on mechanisms of certain disease.
Curative effects of embryonic stem cell transplantation in a wide range of diseases and conditions are far beyond the possibilities of any other modern method.
Embryonic stem cell transplantation is not a magic wand and fulfils realistic tasks: restores lost functions, reduces deterioration, inhibits aging, compensates or substitutes for the defects caused by diseases, and greatly improves the quality of life.
Price of the Treatment
Price of the treatment depends on the diagnosis and number of cell suspensions to be used for the treatment of each patient.
The price includes:
- airport-hotel/apartment-airport transfer
- everyday transportation to and from the clinic
- medical examinations
- tests
- treatment itself
- medical report and follow-up
- medications and additional tests and exams if necessary.
Stem Cells Promise for Treatment of Patients and its Reality
Clinical Stem Cell Transplantation is not then newborn branch of medicine and has already received the first Nobel Prize (1990) for contribution to the "treatment of human diseases".
Bone marrow was the initial source of stem cells used for clinical application starting from late 1960's. Stem cells from dead human fetuses (FSC) were used for treatment of severe immune and blood diseases in children and adults starting from 1970's. Stem cells from cord blood of a newborn were a good option for treatment of this same person later, if needed. All these sources of stem cells are legal for therapeutic use in most countries (fetal stem cells – in EU since 1979, in USA since 1994).
In 1998 viable embryos following artificial in vitro fertilization were declared a new promising source of stem cells. Probably, everybody has heard of the debates on the approval of this source. Well… The Medical community has never offered to use viable embryos – neither fresh, nor preserved, "spare" or "donated" - as a medicine or as a source for medicine.
Despite this, they might be as good for clinical purposes as FSC. Pluripotent stem cells that can develop into cells of the three major tissue types can also be derived from this source, as from certain fetal tissue.
The research for creation of a robust daily clinical method for FSC continued during 1970's and 1980's in about 20 countries, and multiple study results were published in top medical scientific journals, but failed.
Some very good results proved the high curative potential of stem cells, as phenomena. At the same time, poor statistic results in groups of patients indicated the absence of a reliable technological solution and the lack of a safe and efficient method for clinical use of FSC. By the late 1980's clinical branch of FSC transplantation (FSTC) was almost abandoned.
The restart of clinical FSCT happened in early 1990’s after Prof. Alexander Smikodub (National Medical University, Center EmCell, Kiev, Ukraine) created a safe clinical method for FSCT with stable clinical results.
And what was the stunning benefit – this method allowed transplantation without rejection of transplants in absence of immune suppression!
The method allowed avoiding histocompatibility barrier instead of crushing it, like in organ and bone marrow transplantation (by means of conditioning and immune suppression). Among all stem cells, only certain FSC allow for transplantation without rejection and with no immune suppression required.
This was the fulfillment of an unbelievable dream of transplantology – the host totally accepts the transplant! No rejection, no crisis, no conditioning disabling immune system of the host, no life long immune suppression needed, and no weakened immune protection against infection and cancer.
In 1998 the first US patent for FSC treatment of HIV/AIDS was granted to EmCell (Kiev, Ukraine). Several Patents (Ukraine, US, EC, Russia) were granted during 1996-2002 for treatment of Diabetes, AIDS, and some other diseases.
First, we treated patients with severe hematological diseases, immunodeficiency, and Diabetes Mellitus. Then indications for FSCT became more and more widespread. The procedure of FSCT was refined.
At the 4th Congress of the International Cell Transplant Society in 1999 (Montreux, Switzerland) all five reports on clinical use of FSCT were presented by Cell Therapy Clinic of National Medical University and Center EmCell, Kiev, Ukraine (since 1994).
As well as the only clinical report on treatment with the use of FSCT at the First European Conference on Cellular Therapy in Pasteur Institute in Paris (2000).
EmCell has thus far contributed to nearly 40 international conferences, accepted patients from about 50 countries, and has been featured by first rank magazines (Sunday Times, Boston Globe, Spiegel, Max) and TV (ZDF, BBC).
Own EmCell's experience exceeds 5000 FSC transplantations for various diseases and conditions. This is the largest FSC clinical experience in the world so far.
The Guidelines for using FSCT in the treatment of several diseases and conditions were developed on the basis of six post-doctoral multiyear Ph.D. studies. These researches were carried out at the National Medical University and at more than a dozen reputable medical Institutes of the Ministry of Health and Academy of Medical Science of Ukraine (1994-2003). The Guidelines were officially approved (1999–2001) by the Ministry of Health of Ukraine and Academy of Medical Science of Ukraine.
At present, Ukraine apparently has the highest level of preparedness for wide-scale FSCT clinical application.
Practical Side of FSC Transplantations
The most efficient FSCT treatment is related to new-onset diabetes mellitus.
All of a sudden a person faints – and shocking news enters the family. Medicine of civilized world is ready to provide diabetic person with special care.
But keep in mind. Diabetes mellitus is caused by attack of own immune system against special β-cells, producing insulin. The first faint happens when about 80% of β-cells are destroyed, and during the nearest 4-6 months so would be the rest. The remaining 20% would allow healthy life with minor diet limitations. But modern treatment cannot and does not stop this autoimmune aggression. There is no means to stop it now; it may be only to retard. Regular treatment just helps patients to live in absence of own insulin and moderates complications.
The only known modern method to stop autoimmune aggression is FSCT. Your doctor may not be aware of it because the method is rather new, as any patented method should be.
FSCT method for diabetes treatment prevents further destruction of β-cells and allows avoiding development of diabetes mellitus according to regular scenario. This is a real breakthrough.
The most grateful patients for FSCT are elderly people.
Being transplanted, stem cells spread with blood current all over the body. They try to find a place to live. A huge oak prevents other trees from living nearby. So a healthy function or tissue would not allow living of a foreign cell on its territory. Healthy young person would feel no action of FSCT at all.
In this regard, you may understand all the attraction of an elderly person for transplanted stem cells. There is plenty of space within faded tissues to live and to reveal the best features. For an elderly person it means thorough reparation of all faded tissues and many functions. Elderly person has no need to complain or describe what is wrong. Stem cells would find and inhabit all weakened places by themselves. Typical duration of curative effects is 2-3 years, repeated FSCT are allowed and give more long-term effects.
The most crucial circumstances, when FSCT may really save life, are related to conditions of anemia, especially, after chemotherapy.
In chemotherapy there is a fine balance. Chemotherapy, to be efficient in killing more cancer cells, should be aggressive. Aggressive therapy is risky for the patients’ life.
In most cases of strong suppression of hemopoiesis after chemotherapy FSCT allow recovery of blood count within 5-7 days (!) and provide two-threefold reduction of quantity of infectious and hemorrhage complications. So, chemotherapy with FSCT at hand can be more aggressive, efficient and on the other hand even more safe and easier to endure.
Please Click Here to request more information from EmCell Clinic.
Awards & Media Coverage
Prof. Alexander I. Smikodub attended European Congress on Anti-Aging and.....
2008-09-25
Prof. Alexander I. Smikodub attended European Congress on Anti-Aging and Aesthetic Medicine held in Dusseldorf, Germany on September 11-14, 2008 as invited speaker and presented report Embryonic Stem Cells in vivo in Anti-Aging Treatment.
After European Congress on Anti-Aging and Aesthetic Medicine, Prof. Alexander I. Smikodub attended closed seminar Stem Cell Frontiers 2008 organized by Millard Foundation in Chateau Joncmesnil, Belgium and held on September 14-16, 2008. This seminar was dedicated to the new advances in regenerative medicine, and Prof. Smikodub lectured on Clinical Application of Embryonic Stem Cells.
Embryonic Cell Suspensions in Duchenne Muscular Dystrophy
Olexander I. Smikodub
Cell Therapy Clinic of National Medical University of Ukraine and Embryonic Tissues Center EmCell
Under observation were 78 DMD patients aged 3-18. Diagnosis was confirmed by the genetic analysis. Patients were administered mesenchymal, ectodermal, and endodermal stem cells isolated from germ layers of 4-8 weeks old cadaverous embryos’ systems and organs; amounts administered - 0,5-3 ml, cell count- 0,1-100x105/ml. In the course of the first two months after the treatment, strength of different muscle groups increased by 100-700% and was maintained for 8-15 months. Besides, reported was also ROM increase, within the limits of the patient’s stage: stage II patients reported improved gait quality, ability to step on the heel and walk the stairs, raise from the floor with more confidence, and endure bigger loads during the day. Observed were also decreased pseudohypertrophy and strain of forearms and calves, contractures of knee and ankle joints, subsidence of myocardiopathy manifestations and respiratory insufficiency, especially in stage IVa-IVb patients. DMD patients require continuous treatment (at least, once every 6-8 months) aimed at aversion of muscular atrophy progression. Termination of the treatment results in further progression of the disease and limitation of physical activity. Transplantation of embryonic stem cells terminates DMD progression, notwithstanding the stage of the process, and results in marked improvements.
Please Click Here to request more information from EmCell Clinic.
